TaperMD is a web-based clinical decision support system and clinical monitoring pathway that provides prescribers with tools and resources integrated with a proven methodology to manage, communicate and review patient medication plans with a focus on reducing the medication burden in a systematic and holistic manner.

TaperMD is a revolutionary approach to medication management developed through research at McMaster University in Canada to address the serious problems of polypharmacy and drug adverse events.

The team is run by experts in their field, Dr Dee Mangin fills the role of Chief Medical Officer for TaperMD. Dr Mangin is a family doctor originally from New Zealand, where she was a director of the Primary Care Research Unit at Otago University in Christchurch.

Dee moved to Canada in 2013 to become the David Braley Nancy Gordon Chair in Family Medicine and Research Director at McMaster University in Ontario, Canada. Her research is focussed on multi-morbidity, polypharmacy, and matching medical care to patients’ priorities and preferences.

An advocate for better independent information for patients and their doctors on drugs, Dee sits on the Section of Researchers’ Council with the College of Family Physicians of Canada (CFPC) and is a member of the Canadian Patient Safety Institute.

Dr David Healy is an internationally respected psychiatrist, psychopharmacologist, scientist, and author. A professor of Psychiatry at Bangor University in Wales, David is a former Secretary of the British Association for Psychopharmacology, and has authored more than 200 peer- reviewed articles and 20 books. David has been involved as an expert witness in homicide and 
suicide trials involving psychotropic drugs, and in bringing
problems with these drugs to the attention of American and
British regulators.

At IZY we assist TaperMD in an advisory capacity and feel very honoured to work alongside a company that has the aim of improving human wellbeing on a global scale. We are very excited for our collaborative future working together to help them achieve their vision.


Project Blu

“Izy Capital is a rare breed of early stage venture and advisory that understands the complexities of modern financing, entrepreneurship and global delivery.  Their reach is extraordinary, as is their vision.  I never feel that Dave and the team have anything other than our interests at the core of everything they do”

Geryn Evans, CEO Project Blu


“David and the whole Izy Capital team are, simply, great partners.  Approachable, direct, and always mindful of the risk/reward relationship in our growth, their vision, modelling and process management is exemplary.  Dave always sees the bigger picture and endgame and above all deals with everyone with a level of humility which is so refreshing”

Phil Davies, CEO Flyform

Mindful Work

Izy and more specifically David has enabled us to be laser focussed on delivery and customer segmentation. In a competitive market segment Dave has guided us to create a value proposition and outcomes orientated approach that is aligned with our mission of helping 500m to be more Mindful in their approach to life and others by 2025

Simon Michaels

Subscribe to our mailing list

Izy Capital is a trading name of Izy Capital Partners. Company Number: 12637862.
Address: 71 -75 Shelton Street, London, WC2H 9JQ
Web Design and Development By Glue Studio